Show simple item record

dc.contributor.authorSequist, Lecia V
dc.contributor.authorYang, James Chih-Hsin
dc.contributor.authorYamamoto, Nobuyuki
dc.contributor.authorO'Byrne, Kenneth
dc.contributor.authorHirsh, Vera
dc.contributor.authorMok, Tony
dc.contributor.authorGeater, Sarayut Lucien
dc.contributor.authorOrlov, Sergey
dc.contributor.authorTsai, Chun-Ming
dc.contributor.authorBoyer, Michael
dc.contributor.authorSu, Wu-Chou
dc.contributor.authorBennouna, Jaafar
dc.contributor.authorKato, Terufumi
dc.contributor.authorGorbunova, Vera
dc.contributor.authorLee, Ki Hyeong
dc.contributor.authorShah, Riyaz
dc.contributor.authorMassey, Dan
dc.contributor.authorZazulina, Victoria
dc.contributor.authorShahidi, Mehdi
dc.contributor.authorSchuler, Martin
dc.date.accessioned2014-07-29T09:20:11Z
dc.date.available2014-07-29T09:20:11Z
dc.date.issued2013-09-20
dc.identifier.citationSequist LV et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. 2013, 31 (27):3327-34 J. Clin. Oncol.en_GB
dc.identifier.issn1527-7755
dc.identifier.pmid23816960
dc.identifier.doi10.1200/JCO.2012.44.2806
dc.identifier.urihttp://hdl.handle.net/10147/323888
dc.description.abstractThe LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against EGFR mutations. A phase II study of afatinib in EGFR mutation-positive lung adenocarcinoma demonstrated high response rates and progression-free survival (PFS).
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncologyen_GB
dc.subjectLUNG CANCERen_GB
dc.subjectCHEMOTHERAPYen_GB
dc.subject.meshAdenocarcinoma
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCisplatin
dc.subject.meshFemale
dc.subject.meshGlutamates
dc.subject.meshGuanine
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshMutation
dc.subject.meshNeoplasm Metastasis
dc.subject.meshQuinazolines
dc.subject.meshReceptor, Epidermal Growth Factor
dc.titlePhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.en_GB
dc.typeArticleen
dc.contributor.departmentLecia V. Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA; James Chih-Hsin Yang, National Taiwan University Hospital; Chun-Ming Tsai, Taipei Veterans General Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Kenneth O'Byrne, St James' Hospital, Dublin, Ireland; Vera Hirsh, McGill University, Montreal, Quebec, Canada; Tony Mok, Prince of Wales Hospital, Hong Kong, China; Sarayut Lucien Geater, Songklanagarind Hospital, Songkla, Thailand; Sergey Orlov, Pavlov State Medical University, St Petersburg; Vera Gorbunova, GU Russian Oncological Research Centre, Moscow, Russia; Michael Boyer, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Jaafar Bennouna, Institut de Cancérologie de l'Ouest-site René Gauducheau, Nantes, France; Ki Hyeong Lee, Chungbuk National University Hospital, Cheongju, South Korea; Riyaz Shah, Maidstone and Tunbridge Wells National Health Service Trust, Maidstone Hospital, Maidstone; Dan Massey, Victoria Zazulina, and Mehdi Shahidi, Boehringer Ingelheim, Bracknell, United Kingdom; and Martin Schuler, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.en_GB
dc.identifier.journalJournal of clinical oncology : official journal of the American Society of Clinical Oncologyen_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
html.description.abstractThe LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against EGFR mutations. A phase II study of afatinib in EGFR mutation-positive lung adenocarcinoma demonstrated high response rates and progression-free survival (PFS).


This item appears in the following Collection(s)

Show simple item record